This Drink May Lower Your Dementia Risk by 25%, New Study Says
Drinking 2.5 cups of green tea per day was associated with a 25% reduced risk of dementia.
Other foods with the same antioxidants as green tea include dark chocolate and berries.Brain health has become a popular topic as scientists continue to study the brain in more depth. And while there is still much to learn about the brain, one thing we do know is that dementia is on the rise. We recently reported on a study that suggests that new dementia cases may double from half a million to a million per year by the year 2060. Since we know more about the brain and how to take care of it than we did just a few years ago, this estimation is pretty astonishing.
Dementia is a general term for a loss of memory, language, problem-solving skills and other abilities that are severe enough to interfere with everyday life. Alzheimer's disease is the most common type of dementia.
We know that nutrition plays a large role in brain health. There's even a diet designed specifically to provide brain-healthy nutrients, called the MIND diet. Scientists also consider specific foods to see if there is any correlation between them and decreased disease risk. This is what researchers from Japan did regarding green tea and dementia risk. They recently published their findings in The Journal of Nutrition, Health and Aging. Let's break down what they found.
Researchers drew data from a long-running Japanese study called the Murakami study. This study included 13,660 people, about 52% women with an average age of 59.
Some of the demographics adjusted for during statistical analysis included sex, age, BMI, physical activity, smoking status, alcohol consumption, education level, marital status and medical history. Participants also filled out food frequency questionnaires asking how much and how often certain foods and beverages were consumed, including tea and coffee. Baseline data was collected between 2011 and 2013, and the average follow-up time for each participant was 11.5 years.
For tea and coffee, participants were given the following options for their intake: <1 cup per week, 1-2 cups per week, 3-4 cups per week, 5-6 cups per week, 1 cup per day, 2-3 cups per day, 4-6 cups per day, 7-9 cups per day, and 10 cups per day. Options were also given for canned and bottled tea and coffee, and amounts were calculated into the total intake.
It's important to note that 'a cup' can be interpreted as different amounts in studies and, in this case, is not equal to our American-sized measuring cup. For this reason, researchers calculated consumption into milliliters per day and then placed participants into one of four quartiles (categories). Q1 drank <94 mL of green tea per day, Q2 drank 94-299 mL/day, Q3 drank 300-599 mL/day and Q4 drank ≥ 600 mL/day.
Because they were looking specifically for associations between tea and dementia risk, researchers also gathered data regarding dementia from Japan's long-term care insurance (LTCI) database. In the LTCI, physicians assess the degree of dementia and classify patients into six ranks ranging from no dementia (0) to severe dementia-related behavioral impairment and cognitive impairment requiring treatment (V)—basically using Roman numerals, plus the number 0. Those with rank II (moderate dementia-related behavioral disturbances and cognitive dysfunction with mild dependence) or higher are considered to have dementia.
After running statistical analyses, researchers found that those in the higher quartiles for green tea intake had a lower risk of dementia. Specifically, those in the highest quartile, who drank at least 600 mL (or 20 fluid ounces) per day, had a 25% lower risk of dementia compared to those in the first quartile.
They also broke it down by cups of green tea consumed. Participants saw about a 5% reduction in dementia risk for each cup increase in green tea. For example, if someone averaged a cup of green tea a day, they may decrease their risk of dementia by 5%. For someone who drinks 2 cups a day, the reduction in risk goes to 10%. Keep in mind, though, that these cups are not what we consider a measuring cup amount—they're actually closer to about ½ cup. As an example, Q4 drank at least 600 mL of green tea a day, which is equal to about 2.5 American measuring cups, and reduced their risk of dementia by 25% compared to those in Q1.
Because there is some evidence that coffee may decrease dementia risk, researchers were curious to know if those who drank both coffee and green tea might lower their risk even more. Turns out, unlike those who drank a lot of green tea, adding high levels of coffee in addition to green tea did not have the same effects as green tea alone, and showed no reduction in dementia risk.
Researchers propose a couple of possible reasons for this. First, drinking both green tea and coffee in high doses might have a sort of overdose effect, especially regarding caffeine. As an example, green tea contains 20 mg of caffeine per 100 mL dose, and coffee contains 60 mg of caffeine for the same amount. During the combined portion of this trial, participants in Q4 consumed at least 600 mL/day of green tea and 300 mL/day of coffee, which averages out to 300 mg of caffeine per day. And some were drinking well beyond these amounts. The current recommendation for caffeine is no more than 400 mg/day, so those in Q4 were definitely near or beyond that amount.
Researchers also note that coffee and tea contain different plant compounds and that they may counteract each other. But they seemed to lean more into the caffeine theory.
There are a few limitations to this study. One is that participants' cognitive status was not assessed at baseline. So there's a chance that those who had lower cognitive function at the start of the study drank less green tea. If this is true, then the association between green tea and reduced risk of dementia would be weaker. Also, because green tea consumption was estimated based on self-reports, it leaves room for bias and inaccuracies. Lastly, the type of dementia wasn't investigated, so they can't say which types of dementia green tea may reduce. Researchers do note, however, that because it's estimated that Alzheimer's disease makes up about two-thirds of dementia cases, green tea may help reduce the risk of Alzheimer's.
All types of true teas—green, black, white and oolong—are loaded with antioxidants. They are, after all, plants, and all plants contain antioxidants. But compared to the others, green tea has been shown to have the highest levels of catechins, a specific type of flavonoid antioxidant, providing about four times more catechins than black tea. One of these catechins is epigallocatechin3-gallate (EGCG), which researchers note in previous studies has been linked to reduced Alzheimer's risk. Reasons for this may be due to EGCG's ability to reduce inflammation, including in the brain, plus reduce amyloid-beta and tau-tangle accumulation, both of which are implicated in Alzheimer's disease.
That's not to say that other teas don't have their own benefits. For example, black tea may help you live longer, and ginger tea can help ease an upset stomach and reduce arthritis pain. Mint tea has been shown to have digestive, respiratory and mental health benefits, as well as antimicrobial and antiviral properties.
Besides brain health, green tea has also been associated with lower inflammation, better digestion, less bloating, improved blood sugar and cholesterol levels, and reduced risk of cancer.
It's easy to add green tea to your life. Simply brew up a cup. Ideally, we recommend using loose-leaf tea and steeping it in a tea strainer. The reason for this is that some tea bags have been shown to contain microplastics. These tiny particles may end up steeping from the bag into your cup of tea and ultimately into your body, including your brain. If you're looking to limit your microplastic exposure, a tea strainer may be the best steeping option.
Plain green tea is best, but adding a small amount of honey or sugar or a touch of milk is fine if that's how you prefer it. Just be mindful of how much you add, since too much added sugar has been associated with worse brain health, including dementia. If you want to get to zero additions in your tea, take your usual amount of sweetener and/or cream and begin reducing that amount each week until you're at nothing but the tea. Doing this gradually will help your taste buds adjust. It's also important to point out that the longer you steep your tea, the more bitter it's likely to become. If you don't care for the bitterness, go with shorter steeping times.
If you're not a tea drinker (and even if you are) and want the benefits of catechins, there are a few options for you. Dark chocolate, cherries and berries, including blackberries, raspberries and strawberries, are rich in these powerful plant compounds. Dark chocolate and walnuts make a great brain-healthy snack. And cherries and berries are amazing in smoothies, including our Cherry-Mocha Smoothie, Raspberry-Kefir Power Smoothie and our Berry-Green Tea Smoothie, which provides catechins from both berries and green tea.
If you're ready to really dive into eating for brain health, then you'll want to try our 30-Day MIND Diet Meal Plan for Cognitive Health or our Simple 7-Day Cognitive Health Meal Plan.
This study suggests that higher consumption of green tea is associated with reduced risk of dementia, compared to those with little to no green tea intake. Other lifestyle habits also contribute to brain health, including overall diet, physical activity, managing stressors and getting plenty of quality sleep. If this feels overwhelming and you're not sure where to start, choose an area you're likely to have success in. Adding a couple of cups of green tea each day could be an easy addition and starting point.
Read the original article on EATINGWELL
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sanofi agrees to invest $25m in Adagene
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) efforts, including the clinical development of muzastotug (ADG126). The anti-CTLA-4 SAFEbody will be developed through a randomised Phase II study for the treatment of microsatellite stable colorectal cancer (MSS CRC). Adagene chairman, CEO and president of R&D Peter Luo stated: 'Expanding our partnership with Sanofi highlights the potential of our SAFEbody platform and the clinical proof of concept for ADG126, our masked anti-CTLA-4 programme and the most advanced of its kind. 'This strategic partnership reinforces our shared vision of ADG126's promise in advanced solid tumours, including MSS CRC, where dose-limiting challenges have hindered anti-CTLA-4 therapies.' As part of the ongoing partnership, Adagene will provide Sanofi with muzastotug for assessment of its efficacy, safety, pharmacokinetics and biomarker data along with other anticancer therapies in more than 100 subjects in a Phase I/II trial targeting advanced solid tumours. Adagene retains global commercial rights to muzastotug. Expanding on their existing agreement from 2022, Sanofi has exercised an option within the partnership that allows it to select a third SAFEbody discovery programme. This programme uses Adagene's technology and expertise in antibody engineering to develop a bispecific therapeutic aimed at undisclosed targets. As of December 2024, the company reported cash reserves of $85.2m. With the additional funds from Sanofi's investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. After the equity investment and strategic partnerships, a representative from Sanofi will become a member of Adagene's Scientific Advisory Board, which offers guidance on the clinical dimensions of the company's operations. "Sanofi agrees to invest $25m in Adagene" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
From Crisis to Cure: Capitalizing on the Urgent Need for Scalable Traumatic Brain Injury Treatment Care Solutions Says Astute Analytica
The global traumatic brain injury (TBI) treatment market is undergoing a significant transformation, fueled by rising global incidence rates, expanding awareness about brain health, and accelerating innovation in diagnostics and therapeutics. TBI, defined as damage to the brain caused by external mechanical force such as blows, jolts, or penetrative injuries, remains one of the most pressing neurological public health concerns worldwide. It stems from various causes, including falls, road traffic accidents (RTAs), sports-related injuries, assaults, and gunshot wounds. The burden of TBI spans across demographics, with elderly populations predominantly affected by falls, young adults and working-age groups disproportionately impacted by vehicular accidents, and youth increasingly suffering from sports-related TBIs. Chicago, July 02, 2025 (GLOBE NEWSWIRE) -- The global traumatic brain injury market (TBI) treatment market is projected to grow from USD 2.5 billion in 2024 to USD 4.7 billion by 2033, reflecting a robust compound annual growth rate (CAGR) of 7.2% during the forecast period. This expansion is supported by several market forces, including technological advances in neuroimaging and minimally invasive diagnostics, government-backed research initiatives, and increased adoption of personalized rehabilitation protocols. Rising awareness of the long-term consequences of brain injuries, especially mild traumatic brain injuries (mTBIs), such as concussions, is playing a key role in catalyzing early intervention and boosting public engagement in prevention efforts. The increasing prevalence of TBIs among children and adolescents participating in organized sports is of particular concern. According to the CDC (2024), over two-thirds of concussions in high school sports are caused by athlete-to-athlete collisions, with baseball and basketball presenting especially high risks. Moreover, Stanford Children's Health reports that approximately 21% of the 3.5 million annual sports injuries among U.S. children are TBIs, underscoring the need for early diagnostic tools and tailored interventions for younger populations. Request Sample Pages: Epidemiological trends further emphasize the widespread impact of TBIs. Among adults aged 75 and older, falls account for 32% of TBI-related hospitalizations and 28% of deaths, while 81% of emergency visits in those over 65 are due to fall-related TBIs. Working-age adults (18–64 years) also carry a significant burden, mainly due to RTAs and occupational hazards. For instance, a 2020 study from Brazil analyzing 800 motor vehicle accident-related TBIs revealed a strong concentration among males in their 20s, highlighting gender- and age-related vulnerabilities. In children, nearly half of TBI emergency visits result from falls. Gender disparities are also prominent, with males experiencing nearly double the hospitalization rate of females. Market momentum is further bolstered by international research and funding commitments aimed at enhancing TBI care. A prime example is Australia's Traumatic Brain Injury Mission, launched under the Medical Research Future Fund (MRFF), which has allocated $50 million to support studies focused on recovery prediction and effective care models. Such initiatives catalyze the development of advanced tools for functional recovery assessment, predictive analytics, and AI-driven rehabilitation platforms. However, despite this optimistic outlook, the market continues to face significant restraints, most notably the high cost of treatment. The economic burden of TBI care, particularly in low- and middle-income countries (LMICs), limits access and poses barriers to widespread adoption of advanced therapies. In the U.S., treating a mild TBI can cost around $85,000, with moderate to severe cases reaching $900,000 to $3 million over a lifetime. Costs cover emergency care, imaging, hospitalization, and long-term rehabilitation. A single CT or MRI may cost $5,000–$8,000, while inpatient stays average $31,000. Rehabilitation is especially costly, with residential care at $1,000–$2,500 per day and physical therapy at $50–$250 per hour. These high costs strain healthcare systems, highlighting the urgent need for affordable, scalable TBI care solutions. Nevertheless, the future of the traumatic brain injury (TBI) treatment market remains promising. Driven by innovations in diagnostics, early intervention strategies, and support by public and private investment, the sector is rapidly transitioning toward more comprehensive and patient-centric approaches. Continued research into biomarkers for brain trauma, along with the adoption of personalized treatment protocols, is expected to improve outcomes and reduce long-term disabilities. As road traffic safety infrastructure improves in developing regions and awareness grows around the importance of helmet use and sports safety, incidence rates may stabilize. Therefore, the traumatic brain injury (TBI) treatment market is poised for transformative growth that could reshape neurological care and improve the lives of millions affected by traumatic brain injury. Market Forecast (2033) USD 4.7 billion CAGR 7.2% Top Driver Growing incidence of TBIs due to increasing sports injuries and road accidents Top Trend Rising Personalized & Targeted Therapies in Traumatic Brain Injury (TBI) Top Challenge High cost of treating traumatic brain injuries AI and ML Integration: Transforming TBI Diagnosis, Personalization, and Recovery Pathways The integration of artificial intelligence (AI) and machine learning (ML) into traumatic brain injury (TBI) care is redefining how clinicians diagnose, monitor, and treat brain trauma ushering in a new era of precision medicine and outcome-driven recovery strategies. Traditionally challenged by diagnostic variability and limited tools for predicting long-term effects, the TBI field is now being transformed by AI technologies that enable real-time imaging analysis, individualized treatment planning, and improved prognostic accuracy. A notable advancement lies in the deployment of AI-enhanced CT imaging and ML-based predictive models, currently under clinical investigation, which offer dynamic insights into injury progression and long-term functional outcomes. These tools help clinicians adapt rehabilitation protocols based on patient-specific risk factors, significantly improving the efficiency and effectiveness of care delivery. Technology companies and healthcare providers are forging strategic partnerships to accelerate the adoption of these tools, while research institutions continue to validate their clinical utility across diverse populations. These developments not only strengthen diagnostic precision and care quality but also reduce treatment costs, enhance patient monitoring, and open new frontiers in digital therapeutics. Global Traumatic Brain Injury (TBI) Treatment Market: Regional Trends Shaping the Future of Neurotrauma Care The global traumatic brain injury (TBI) treatment market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa, with North America retaining a leading position in 2024. The United States alone reports approximately one million emergency department visits for TBI each year, with over 230,000 hospitalizations and 80,000 individuals discharged with lasting disabilities, primarily due to road accidents and sports injuries. The region's dominance is supported by a well-established healthcare infrastructure, high healthcare expenditure, and strong uptake of advanced therapeutic technologies. Organizations such as the International Brain Injury Association (IBIA) and major academic trauma centers contribute significantly to clinical research, innovation, and patient support. Additionally, the availability of specialized rehabilitation programs and growing investments in neurotrauma care continue to support market expansion. Following North America, Europe holds a significant share of the global TBI treatment market, particularly led by countries like Germany, the United Kingdom, and France. A high incidence of fall-related TBIs, especially among the elderly, drives the demand for both acute care and long-term rehabilitation. Europe is advancing its position through initiatives such as the UK's TBI-REPORTER, a $12.61 million research project spearheaded by the University of Cambridge to consolidate patient data and accelerate treatment innovation. Robust public healthcare systems and integrated care pathways across the EU further enhance treatment accessibility and outcomes. The Asia-Pacific region is expected to witness the highest compound annual growth rate (CAGR) in the TBI treatment market. Rapid urbanization, rising road traffic injuries, and improving healthcare infrastructure in countries like China, India, Japan, and Australia are key growth drivers. Notably, Japan has approved AKUUGO, the world's first stem cell therapy for chronic TBI, signaling the country's leadership in treatment innovation. Meanwhile, China continues to invest heavily in TBI-related R&D in response to its high neurotrauma mortality rate of 13 per 100,000 people, aiming to improve early diagnosis and treatment accessibility. While growth in South America and the Middle East & Africa remains gradual, the outlook for market expansion is increasingly promising. In the MEA region, the rising incidence of road traffic injuries is driving government and private sector investments in trauma care infrastructure particularly in countries like the UAE and Saudi Arabia, where the development of specialized trauma centers is gaining momentum. Similarly, South America is witnessing early progress, fueled by public-private partnerships and growing awareness initiatives aimed at enhancing neurotrauma care. As healthcare infrastructure strengthens and supportive policies take shape, both regions are poised to play a more prominent role in shaping the global TBI treatment market in the years ahead. Recent Advancements and Key Players in the Traumatic Brain Injury (TBI) Treatment Market Several key players, including Cellvation, Oragenics, Oxeia Biopharmaceuticals, BioVie, Shinkei Therapeutics, Abliva/Owl Therapeutics, and other prominent companies, are at the forefront of innovation in the traumatic brain injury (TBI) treatment market. These organizations are driving progress through the development of novel therapeutics, advanced biologics, and regenerative medicine approaches aimed at improving patient outcomes and addressing unmet clinical needs in TBI care worldwide. For instance, in a significant advancement for TBI diagnostics, DRG Neuroscience (a division of DRG Instruments GmbH) announced the launch of its automated chemiluminescence immunoassay (CLIA) tests in January 2025. These rapid diagnostics, built on DRG's DxDATA platform, are designed to measure GFAP and UCH-L1 blood biomarker levels key indicators of brain injury within 30 minutes, provided samples are collected within 12 hours of suspected TBI occurrence. These tests are CE-marked and CLSI-verified, reflecting adherence to international standards and expanding accessibility to timely and accurate TBI diagnosis. On the therapeutic front, SanBio Inc. achieved a milestone with the July 2024 time-limited marketing approval in Japan for AKUUGO (Vandefitemcel), the world's first allogeneic bone marrow-derived mesenchymal stem cell therapy approved for chronic motor paralysis following traumatic brain injury. Approved for intracranial implantation, AKUUGO is based on promising outcomes from a global Phase II clinical trial and marks a transformative shift in the treatment of chronic TBI offering new hope for patients with limited recovery options. Modify Report as Per Requirements: Future Outlook: Advancing the Traumatic Brain Injury Treatment Market The traumatic brain injury (TBI) treatment market is poised for significant expansion, driven by ongoing innovations in neuro regenerative therapies, biomarker diagnostics, and personalized medicine. Rising global incidence of TBI, coupled with growing awareness and improved diagnostic capabilities, is creating substantial opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers to transform patient outcomes. Industry leaders anticipate accelerated development and regulatory approval of novel treatments including stem cell therapies, neuroprotective agents, and advanced surgical interventions that target the complex pathology of TBI. Cutting-edge technologies such as biomarker-driven diagnostics, artificial intelligence (AI)-enhanced imaging, and minimally invasive procedures are expected to streamline early diagnosis and optimize therapeutic strategies. The emergence of regenerative approaches, including mesenchymal stem cell therapies and gene-modified cellular treatments, holds promise in repairing neural damage and improving functional recovery in chronic TBI patients. Companies like Cellvation, Oragenics, and Shinkei Therapeutics are at the forefront of pioneering research and clinical trials, aiming to deliver transformative solutions across acute care and rehabilitation phases. Investment in infrastructure, such as specialized trauma centers and integrated rehabilitation programs, alongside government initiatives supporting neurotrauma research, will further catalyze market growth. Regulatory frameworks are evolving to facilitate faster approvals of breakthrough therapies, while reimbursement models are gradually adapting to cover innovative treatment modalities. By 2030, TBI treatments are expected to become more personalized, accessible, and integrated within multidisciplinary care pathways, fundamentally changing the prognosis for TBI patients worldwide. The convergence of advanced therapeutics, data-driven clinical decision-making, and scalable manufacturing will be crucial in overcoming current challenges. Continued exploration of allogeneic cell therapies and neuroprotective biologics promises to unlock new avenues for healing and functional restoration, shaping the future landscape of traumatic brain injury management. Key Competitors Cellvation Oragenics Oxeia Biopharmaceuticals BioVie Shinkei Therapeutics Abliva/Owl Therapeutics Other Prominent Players Segmentation of Amyotrophic Lateral Sclerosis Treatment Market By Treatment Type Medication Anti- seizures drugs Diuretics Pain relievers Antidepressant Stem Cell Therapy Surgery Others (Rehabilitation Therapies, Physiotherapy, etc) By Route of Administration Intravenous Oral Others By Distribution Channel Hospital & Rehabilitation Centres Pharmacies Retail Pharmacies Online Pharmacies By Region North America South America Europe Asia-Pacific Middle East and Africa Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Fox News
7 hours ago
- Fox News
Breast cancer survivors may have lower risk of developing Alzheimer's disease, study finds
Cancer is not typically associated with health benefits, but a new study suggests that it could reduce the risk of dementia for some patients. A study led by the Seoul National University College of Medicine suggests that breast cancer survivors could have a slightly lower chance of developing Alzheimer's disease compared to those who had not undergone treatment. In the study, which was published in JAMA Network Open, data from more than 70,000 breast cancer survivors were compared to a cancer-free control group for an average of 7.3 years. Overall, the breast cancer survivors — particularly those who were 65 and older — showed an 8% lower risk of dementia within the five years following treatment. Those who received radiation showed the most risk reduction, the researchers found. The study was adjusted for other factors that could have contributed to Alzheimer's risk, including age, income levels, geographic location, body mass index, comorbidities (diabetes, hypertension, high cholesterol and chronic kidney disease) and health-related behaviors (smoking, alcohol consumption and physical activity), the study stated. This outcome conflicts with previous concerns about breast cancer patients experiencing cognitive decline after treatment. Chemotherapy has previously been linked to a condition called "chemo brain," where patients experience cognitive decline. "Chemo brain refers to cognitive dysfunction, including thinking and memory problems, that occur in patients with cancer during and after chemotherapy," the researchers wrote. This is different from Alzheimer's, however — with "chemo brain," the cognitive impairment is described as "subtle" and doesn't keep the patient from retrieving remote memories. "Concerns about chemo brain and the long-term adverse effects of breast cancer treatment on cognition are common, but our findings suggest that this treatment does not directly lead to AD," the researchers noted. In fact, they stated, some studies have shown that certain drugs given to breast cancer patients can help to reduce the formation of amyloid-beta and tau proteins in the brain, which is one of the hallmarks of Alzheimer's. Based on the findings, the researchers recommend that breast cancer patients take steps to reduce modifiable risk factors for Alzheimer's, such as smoking and diabetes, along with receiving standard cancer treatment. The study did have some limitations, the team acknowledged. Information about patients' breast cancer stage and radiation dose was not available. It is also possible that the number of Alzheimer's diagnoses was underestimated. Also, because the study focused on patients with "operable" breast cancer, it may not represent the risk of Alzheimer's among elderly patients, those with "critical comorbidities" or patients with advanced-stage disease, the researchers noted. "We could not evaluate the long-term increase in AD risk because our follow-up period was relatively short (maximum, 11 years)," they wrote. "Additional studies with long-term observation periods are warranted to examine long-term associations between AD risk and breast cancer survival duration." Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead in Chicago, pointed out that this topic of research has been explored in previous studies. "There have been many published reports from observational studies of cancer survivors with decreased risk of Alzheimer's disease, but also some that found increased risk," Carrillo, who was not involved in this most recent study, told Fox News Digital. The expert cautions against drawing "abrupt conclusions" based on this study. "Previous research on cancer survival and treatment and Alzheimer's risk, much of it cited by the authors of this article, has produced mixed — even contradictory — results," Carrollio said. "More research is needed — especially longer studies in more representative study populations." The most interesting aspect of this study, Carrillo said, is the finding that radiation therapy was associated with 23% Alzheimer's risk reduction, while other cancer treatments showed no risk reduction. This could be due to radiation's capability to lower inflammation levels, the expert suggested. For more Health articles, visit "Lowering inflammation in the body and brain can reduce amyloid beta or slow amyloid beta production, delaying the onset of symptomatic Alzheimer's," she said. "More research is needed to see if this is, in fact, the case." Approximately 7.2 million Americans aged 65 and older are currently living with Alzheimer's, according to the Alzheimer's Association. Fox News Digital reached out to the study researchers for comment.